Skip to main content

Advertisement

Combination strategies

Section edited by Paolo A. Ascierto

This section aims to provide a focal point for research that highlights combination therapies, where two or more medications or therapies are strategically combined to improve the treatment of cancer, chronic infections, transplantation and potentially other complex and multi-factorial diseases.

Increasingly detailed understanding of the molecular basis driving complex disease has led to the identifications of new agents that target specific pathways. In some cases treatment of appropriately selected patients has led to striking clinical response, however both primary and secondary resistance mechanisms limited the success of many of these agents. It has become clear that combining or sequencing treatment modalities may en to enrich the communication between basic biological and immunological sciences and the clinical investigation arena.

Featured articles

Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells
Takashi Shingu, et al


Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
Jenny E Hernandez-Davies, et al


What’s new in melanoma? Combination!
Paolo A Ascierto, Francesco M Marincola and Michael B Atkins

Page 3 of 3

  1. HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with anthracyclines. The aim of this study was to comprehensively eva...

    Authors: George Fountzilas, Christos Valavanis, Vassiliki Kotoula, Anastasia G Eleftheraki, Konstantine T Kalogeras, Olympia Tzaida, Anna Batistatou, Ralf Kronenwett, Ralph M Wirtz, Mattheos Bobos, Eleni Timotheadou, Nikolaos Soupos, George Pentheroudakis, Helen Gogas, Dimitrios Vlachodimitropoulos, Genovefa Polychronidou…

    Citation: Journal of Translational Medicine 2012 10:10

    Content type: Research

    Published on:

  2. Combination of oncolytic vaccinia virus therapy with conventional chemotherapy has shown promise for tumor therapy. However, side effects of chemotherapy including thrombocytopenia, still remain problematic.

    Authors: Julia B Sturm, Michael Hess, Stephanie Weibel, Nanhai G Chen, Yong A Yu, Qian Zhang, Ulrike Donat, Cora Reiss, Stepan Gambaryan, Georg Krohne, Jochen Stritzker and Aladar A Szalay

    Citation: Journal of Translational Medicine 2012 10:9

    Content type: Research

    Published on:

  3. Cancer patients receiving chemotherapy are at increased risk of thrombosis. Nadroparin has been demonstrated to reduce the incidence of venous and arterial thrombotic events (TEs) by about 50% in cancer outpat...

    Authors: Sandro Barni, Roberto Labianca, Giancarlo Agnelli, Erminio Bonizzoni, Melina Verso, Mario Mandalà, Matteo Brighenti, Fausto Petrelli, Carlo Bianchini, Tania Perrone and Giampietro Gasparini

    Citation: Journal of Translational Medicine 2011 9:179

    Content type: Protocol

    Published on:

  4. Platinum-based regimens are the treatments of choice in ovarian cancer, which remains the leading cause of death from gynecological malignancies in the Western world. The aim of the present study was to compar...

    Authors: Chiara Arienti, Anna Tesei, Giorgio Maria Verdecchia, Massimo Framarini, Salvatore Virzì, Antonio Grassi, Emanuela Scarpi, Livia Turci, Rosella Silvestrini, Dino Amadori and Wainer Zoli

    Citation: Journal of Translational Medicine 2011 9:94

    Content type: Research

    Published on:

Annual Journal Metrics

Advertisement